Join
Live feed
·
PRReleasevia Quantisnow
Prometheus Biosciences Inc. logo

Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb

ByQuantisnow·Wall Street's wire, on your screen.
RXDX· Prometheus Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RXDX (Prometheus Biosciences Inc.) and more on Quantisnow.